Study of LY9 as a potential biomarker for prognosis and prediction of immunotherapy efficacy in lung adenocarcinoma
Therefore, we hypothesized that LY9 could serve as a potential, novel prognostic biomarker for LUAD and could predict immunotherapy efficacy at the mRNA level.
Authors
- Liuliu Huang (ORCID: https://orcid.org/0000-0002-5148-3052)
- Zhiwen Zheng (ORCID: https://orcid.org/0000-0001-5982-0968)
- Zhanyu Xu (ORCID: https://orcid.org/0000-0002-6471-1667)
- Yu Sun (ORCID: https://orcid.org/0000-0003-0333-2898)
- Fanglu Qin
- Wei Jiang (ORCID: https://orcid.org/0000-0002-9079-0792)
- Liqiang Yuan
- Tiaozhan Zheng
- Shikang Li (ORCID: https://orcid.org/0000-0002-8187-3676)
- Junqi Qin (ORCID: https://orcid.org/0000-0003-1799-3734)
- Xinhuai Ou
- Liping Zheng
- Kun Deng
Institutions
- Guangxi Medical University (CN)
- Deyang Stomatological Hospital (CN)
- Neijiang Normal University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Xian Yang Central Hospital (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2024-08-23
- DOI
- https://doi.org/10.7717/peerj.17816
- Citations
- 1
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.29